Paul F. Pollack

Neonatology | Pediatric Gastroenterology
2529 E Broad St
Columbus, OH 43209

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: August 08, 2023

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.

Journal: Gastroenterology
Published: January 22, 2021

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.

Journal: Gastroenterology
Published: September 12, 2018

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Journal: Gastroenterology
Published: November 01, 2017

Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.

Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.

Journal: Pancreas
Published: October 27, 2015

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.

Journal: Drugs in context
Published: November 26, 2014

Milk protein-based infant formula containing rice starch and low lactose reduces common regurgitation in healthy term infants: a randomized, blinded, and prospective trial.

Milk protein-based infant formula containing rice starch and low lactose reduces common regurgitation in healthy term infants: a randomized, blinded, and prospective trial.

Journal: Journal of the American College of Nutrition
Published: April 15, 2014

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.

Journal: Alimentary pharmacology & therapeutics
Published: May 15, 2013

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.

Journal: Gastroenterology
Published: May 15, 2013

52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.

52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.

Journal: Inflammatory bowel diseases
Published: May 14, 2013

Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.

Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.

Journal: Pancreas
Published: April 17, 2013

Serum adalimumab concentration and clinical remission in patients with Crohn's disease.

Serum adalimumab concentration and clinical remission in patients with Crohn's disease.

Journal: Inflammatory bowel diseases
Published: April 16, 2013
Showing 1-12 of 16

Last Updated: 09/26/2026